NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

End of life care for infants, children and young people with life-limiting conditions: planning and management

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

No additional equality issues were identified.

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

All new recommendations are centred around individualised circumstances and are not prescriptive in a way as to disadvantage any protected groups.

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No there is not.

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.1, 4.2 and 4.3, or otherwise fulfil NICE's obligations to advance equality?

Not applicable (4.1, 4.2 and 4.3 did not identify any new equality issues.

4.5 Have the Committee's considerations of equality issues been described in the final guideline, and, if so, where?

Equalities issues have been described in the rationale for recommendations where applicable and were also highlighted in the protocols for the reviews.

Updated by Developer	Stephen Murphy, Clinical Advisor
Date	23 September 2016
Approved by NICE quality assurance lead	Sharon Summers-Ma,Guideline Lead
Date	7 October 2016